The balance between Th17 cells and regulatory T cells (Tregs) has emerged as a prominent factor in regulating autoimmunity and cancer. Th17 cells are vital for host defense against pathogens but have also been implicated in causing autoimmune disorders and cancer, though their role in carcinogenesis is less well understood. Tregs are required for self-tolerance and defense against autoimmunity and often correlate with cancer progression. This review addresses the importance of a functional homeostasis between these two subsets in health and the consequences of its disruption when these forces collide in disease. Importantly, we discuss the ability of Th17 cells to mediate cancer regression in immunotherapy, including adoptive transfer and checkpoint blockade therapy, and the therapeutic possibilities of purposefully offsetting the Th17/Treg balance to treat patients with cancer as well as those with autoimmune diseases.
INTRODUCTION

CD4
+ T cells play a critical role in regulating human health and disease by orchestrating the immune system to contend with danger induced by foreign antigens, such as infections or cancer formation. Proper function of the CD4 + T cell compartment relies on an adjustable equilibrium among various T cell subsets, which help trigger the host's immune system in defense against threat. While the division of CD4 support was previously hypothesized to be dominated solely by Th1 and Th2 helper subsets, mounting evidence over the past decade reveals that Th17 cells and regulatory T cells (Tregs) also play important roles in regulating health and exacerbating autoimmunity and cancer. Herein, we will discuss the delicate balance between Th17 and Treg cells in maintaining a healthy, functioning immune environment, as well as the harmful effects that transpire when homeostasis is disturbed and their therapeutic implications. Finally, we discuss the possibilities of harnessing a Th17 response against cancer in adoptive transfer and checkpoint blockade therapy, thus highlighting an approach whereby therapeutically and purposefully offsetting the Th17/Treg balance could be effective in treating human cancers.
Basics of T helper subsets
Before the 1980s, helper T cells were believed to be a single subset among T lymphocytes 1 . Increasing evidence now suggests that there are at least seven distinct T helper subsets differentiated in response to particular combinations of cytokines. These subsets are also controlled by different transcription factors to produce a characteristic milieu of cytokines and exert an effector function against self and foreign antigens. These subsets are described below and summarized visually in Fig. 1 .
CD4
+ T cells differentiate into subsets such as Th1, Th2, Th17, Treg, Th9, Th22, and T follicular helper cells 2 . Th1 cells rely on the expression of T-bet and eliminate intracellular pathogens through IFN-γ production, which activates macrophages [2] [3] [4] . Th2 cells play a role in the presentation of allergens; promote immunity against parasites through production of IL-4, IL-5, and IL-13, and are regulated by transcription factor GATA3 5 . Interestingly, Th2 differentiation is also mediated by IL-4, creating a positive feedback loop to bolster proliferation 2, 6 . Th17 cells secrete IL-17A, IL-17F, IL-21, IL-22, and CCL20, express master transcription factor RORγt, encoded by Rorc
7
, and promote inflammation in response to infections [8] [9] [10] . Regulatory T cells (Tregs) suppress effector function through secretion of inhibitory cytokines such as IL-10 and TGF-β or through cell-mediated engagement of inhibitory checkpoint molecules such as TIGIT and CTLA-4 11 . The relevance of Th17 cells has been documented in promoting autoimmunity, carcinogenesis, and antitumor immunity, whereas Treg cells are essential for immune tolerance and have been shown to dampen autoimmunity and antitumor immunity 6, 12, 13 . Most recently, Th9, Th22, and T follicular helper cells (Tfh) have been described as distinct helper populations. As such, knowledge of the programming cytokines and master transcription factors for these subsets is still somewhat under debate. Th9 cells differentiate in response to IL-4 and TGF-β [14] [15] [16] and produce IL-9 under control of the transcription factors STAT6, PU.1 17 , IRF4 18 , BATF 19 , and FOXO1 20 . IL-9 recruits lymphocytes and mast cells as effectors [21] [22] [23] and is enhanced under the influence of IL-1β and transcription factor IRF1 24 . Th22 cells are polarized by IL-6 and TNF-α to secrete IL-22 25 and have been shown to exacerbate psoriasis in patients 26 . Which transcription factor(s) control Th22 differentiation is less clear 27, 28 . However, several groups have identified aryl hydrocarbon receptor (AHR) as having a vital role in Th22 differentiation 25, [28] [29] [30] , while the role of T-bet is more controversial 25, 30 . Tfh cells classically secrete IL-21 for B cell development in germinal centers, as well as IFN-γ and IL-4 to aid B-cell immunoglobulin class-switching to IgG and IgE in the lymphoid follicle 31 . They also secrete IL-9 to promote B cell memory and differentiation of plasma cells 31, 32 . Although Bcl6 has been the widely accepted transcription factor controlling differentiation of Tfh cells, there are also recent reports suggesting STAT4 and T-bet 33 , c-Maf 34 , IRF4 35 , and Batf 36 are important to differentiation of this lineage.
T helpers in opposition
Our current understanding of T helper function revolves around a theory that subsets are in a state of equilibrium 37 . Upon activation of one particular subset, other subsets are modulated or inhibited in order to promote the most specific effector response in defense influences Th1 cell development and promotes immunity upon the presence of IFN-γ, STAT4, T-bet, and LTα. Th2 cell differentiation is induced by IL-4, during which cytokine release may manifest in allergies or asthma. Th17 cell development occurs following the influence of TGF-β, IL-6, and IL-21. IL-1β and IL-23 maintain Th17 cell stabilization during clonal expansion. Upon differentiation, Th17 cells are most commonly classified by their expression of RORγt and STAT3. Th9, Th22, and Tfh cells have been most recently described, and transcription factors controlling their differentiation remain under debate against imminent threat 37, 38 . Historically, this discussion began with the Th1/Th2 hypothesis of distinct opposing T helper subsets, formulated after searching for a T cell responsible for helping antibody production versus one responsible for tissue damage in delayed-type hypersensitivity (DTH) 39, 40 . Early studies claimed that Th1 cells mediated tissue damage in DTH, not the antibodies in serum, and would likely be the cell responsible for mediating tissue damage in various autoimmune diseases 40 . After several failed attempts to show that tissue damage in murine experimental autoimmune encephalitis (EAE) was mediated by Th1 cells and their effector cytokine, IFN-γ, the characterization of a novel subset called Th17 cells emerged [41] [42] [43] [44] [45] . The Th1/Th17 balance developed, recognizing that IFN-γ and IL-17 have antagonistic properties, as blockade of IFN-γ results in increased IL-17 production by T cells 46, 47 . Finally, an antagonistic relationship between Th17 cells and Tregs has been described, as their differentiation is stimulated by similar cytokines yet they have different functions [48] [49] [50] . Th17 cells serve as an effector lymphocyte population, while Tregs are suppressor cells [48] [49] [50] . Herein, we will focus on the particular Th17/Treg balance of opposing forces in autoimmunity and cancer and the roles of each subset in both promotion of and protection from these pathogenic phenotypes.
The YIN: Th17 cells Differentiation. The emergence of the distinct Th17 lineage can be attributed to studies of central nervous system autoimmunity. Early studies involving the EAE model revealed that IL-23 knockout (KO) mice were resistant to developing EAE, while IL-12 KO mice remained susceptible 51 . This surprising series of experiments signified that Th1 polarization was not critical to the autoimmune phenotype, as was previously posited 51 . IL-23 was subsequently discovered to drive polarization of a pathogenic CD4 + T cell subset characterized by production of IL-17A and IL-17F, which could induce EAE upon adoptive transfer, while IFN-γ producing Th1 cells could not 52 . These IL-17 producing cells were considered a distinct lineage, when the milieu of cytokines supporting their differentiation was shown to be independent of the environment of cytokines required for Th1 and Th2 development 47, 53 . In fact, the in vitro differentiation of naive CD4 + T cells to Th17 cells is suppressed by Th1/Th2 cytokines IFN-γ and IL-4 53 and relies on costimulation by CD28 and ICOS 47 . The cytokines most important to Th17 differentiation are TGF-β, IL-6, and IL-1β, and the phenotype is maintained long term in the presence of IL-21 and IL-23 54, 55 . The role of each of these individual cytokines is discussed below.
Along with IL-6, TGF-β is well known as a critical cytokine for inducing RORγt in naive CD4 + T cells, which in turn drives their differentiation to a Th17 phenotype. However, new findings have provided insight into exactly how TGF-β regulates RORγt. Interestingly, TGF-β was shown to modulate the SKI-SMAD4 complex 56 . The SKI-SMAD4 complex suppresses RORγt, as the SKI protein inhibits acetylation of the Rorc locus 56 . However, in the presence of TGF-β, SKI is degraded, permitting RORγt expression in CD4
+ T cells and ultimately driving Th17 differentiation 56 . Low doses of TGF-β1 also inhibit IL-2-mediated activation of STAT5 and reduce T-bet and GATA3 expression, which inhibits Th1/Th2/Treg differentiation while promoting the Th17 lineage 57 . Recent findings have also demonstrated that phosphatase and tensin homolog (PTEN) in Th17 cells suppresses IL-2 signaling, reducing STAT5 and the Treg pathway while upregulating STAT3, a transcription factor that supports the Th17 pathway 58 . It is also important to appreciate that TGF-β and IL-6 induce the IL-23 receptor (IL-23R) in Th17 cells 59 . 65 . To maintain gut defense, IL-17 upregulates claudins for tight junction formation in the intestinal barrier and IL-22 plays a role in epithelial maintenance 66, 67 . IL-17 induces granulopoeisis indirectly through stimulation of epithelial cells, endothelial cells, and fibroblasts to secrete GM-CSF, IL-6, IL-8, and MIP-2 68, 69 . In turn, IL-8, and MIP-2 enhance chemotaxis of neutrophils 70 . Mice deficient in IL-17R have an impaired ability to repopulate these immune cells after irradiation 71 . Th17 cells and IL-17 have been implicated in immunity against extracellular pathogens, such as Klebsiella pneumoniae 69 , Staphylococcus aureus 72 , Salmonella enterica serovar Enteriditus 73 , and Shigella flexneri 74 among other bacterial species. Th17 cells have also been shown to augment Th1 recruitment in Mycobacterium tuberculosis infection, which is critical to granuloma formation and sequestration of bacteria 75 . These collective Th17 functions are critical in preserving the health of the host and when compromised can lead to various disease symptoms, as discussed below.
Mutations that result in loss of Th17 cell function manifest in disorders such as Job's syndrome, also named hyper-IgE syndrome, and chronic mucocutaneous candidiasis (CMC) disease. Job's syndrome is caused by an autosomal dominant STAT3 inactivating mutation and results in increased susceptibility of patients to S. aureus and Candida albicans 76 . Phenotypically, this disease presents as a triad of eosiniphilia, eczema, and recurrent skin and pulmonary infections 77 . CMC disease, manifested by chronic infection of the skin, nails, and mucosa by C. albicans, is related to any of four inheritable gene defects in IL-17RA, IL-17RC, IL-17F, or ACT1 78 . These mutations impair the host Th17 response and increase susceptibility to infection with extracellular pathogens. Thus, Th17 cell function plays a critical role in regulating immune responses in health and in disease within the host. Based on these findings, translational researchers and physician scientists have been actively investigating methods to regulate the Th17 pathway in patients to treat both autoimmunity and infectious disease.
The Yang: Regulatory T cells Effector functions of the adaptive immune response provide the ability to fight and clear invading pathogens while generating memory against those pathogens for a rapid recall response. Such effector functions, while vital for survival, can be damaging if engaged for too long, driving chronic inflammation, or if directed against self-tissue, causing autoimmunity 38 . As such, effector T cells must be regulated to prevent immune cell defense from turning to offense.
The discovery and recognition of a distinct T cell subset functioning to suppress immune responses was controversial in the late 20th century, and some debate over lineage still exists today. The first discovery that T cells could dampen immune responses was made in 1970, and thereafter, these cells were termed "suppressor" cells 79 . These cells were defined by their expression of the "I-J" molecule, which was claimed to be important to suppressive function 80 . Controversy arose when the I-J coding region could not be identified on murine major histocompatibility complex (MHC) and due to a lack of other concrete identifying markers led to the collapse of the "suppressor" T cell movement 81 . Around that time, it was separately noted that immune tolerance could be broken from the beginning of development. Neonatal thymectomy of mice resulted in destruction of the ovaries, which was later correlated with tissue damage in other organs 82, 83 . Identification of two types of "regulatory" T cells followed-one naturally occurring in the thymus and responsible for clonal deletion of T cells specific to self-antigens and one in the periphery, inducible from naive CD4 + T cells.
Differentiation and function
Several cornerstone discoveries about Tregs include the identification of IL-2Rα (CD25) as a functional marker, the importance of IL-2 for tolerogenic function, and designation of Foxp3 as the master transcriptional regulator. In mice, CD25 marks a population of CD4 + T cells that normalize immune function and prevent lethal autoimmunity 84, 85 100 . Foxp3 is present in natural and peripheral Tregs, although the exact mechanism of generating peripheral Tregs in the context of antigen specificity is still somewhat under debate 101 . Cellular development of Th17 and Treg cells shares a common cytokine, TGF-β, which is needed to induce Foxp3 and RORγt in Treg and Th17 cells, respectively. TGF-β with IL-2 can induce Foxp3 + Treg differentiation peripherally from naive CD4 + T cells, whereas TGF-β plus IL-6 (secreted by the innate immune arm, such as activated dendritic cells) induces the Th17 lineage ( Fig. 1) 48,49,102 . As mentioned previously, IL-6 and IL-21 induce STAT3, which inhibits Foxp3, while IL-2 induces STAT5, which reduces STAT3 binding and inhibits Th17 differentiation 59, [103] [104] [105] . Supplemental IL-2 as therapy for autoimmune disease may augment Treg function and boost self-tolerance. The notion is now well appreciated that generating a regulatory response is closely related to differentiating an effector Th17 response against pathogens. Collectively, the immune system tightly regulates Th17/Treg homeostasis via the TGF-β/IL-2 and IL-6 cytokine axis.
Defects in Treg function lead to unregulated immune responses to self-tissue. Treg function depends heavily on migratory activity -during an immune response, Tregs migrate from blood to lymph nodes and tissues, and the ratio of Treg/non-Treg CD4 + cells in those compartments increases 106 . Recent reports have shown that Treg migration is regulated by bioenergetics. Specifically, glucokinase-dependent glycolysis in Tregs was found to prevent the effector response from generating excess 107 . Without the ability to migrate, Tregs cannot relocate to the site of inflammation, as shown by their reduced ability to suppress allograft rejection 107 . Similarly, inheritable mutations that render Tregs dysfunctional cause lethal autoimmunity. Mutations in Foxp3 result in a disease known as IPEX, which is characterized by immune dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome 108 . This disorder generally presents early after birth with severe dermatitis or psoriaform lesions, watery diarrhea, excessive cytokines, thyroiditis and hypothyroidism and frequently leads to death early in childhood 108 . This mutation impairs the regulatory host response and permits rampant inflammation from other unopposed immune cell compartments.
Th17/Treg plasticity Both Th17 and Treg cells have been described as exhibiting the property of plasticity. Plasticity is defined by the unique ability to adapt to signaling cues in a changing environment. For example, as shown in Fig. 2 115 . It is hypothesized that this conversion is controlled by TGF-β and prostaglandin E2 (PGE2) 115 . This dynamic functionality by Th17s and Tregs reveals the complexity of manipulating these subsets therapeutically.
Th17/Treg in Autoimmunity Th17 cell-mediated immunity is important for maintaining mucosal and hematopoietic homeostasis. However, too strong of a Th17 cell response can induce autoimmunity. Likewise, a lack of Tregs can result in lethal autoimmunity in humans. As detailed in Table 1 , the altered homeostasis between Th17 and Treg has been implicated in several autoimmune diseases, including multiple sclerosis 116, 117 , psoriasis 118 , rheumatoid arthritis 119 , inflammatory bowel disease 120 , and systemic lupus erythematosus 121 . Thus, the relationship between effector Th17 cells and Tregs must remain balanced to preserve functional immunity and health of the host. Some important examples of this Th17/Treg balance in patients are discussed in various autoimmune manifestations below. In addition, recent therapeutics that have been used to reduce the severity of these diseases by modulating the Th17/Treg axis are discussed below.
Multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease involving destruction of myelin in central nervous system white matter. This disease presents in patients as deficits in sensory or motor function, unilateral vision loss, diplopia, gait disturbance, or loss of bladder control, among other varied symptoms of nervous system malfunction. As discussed previously, the experimental mouse model of MS is EAE, from which came the discovery of Th17 cells and their role in neuroinflammation. In MS patients, myelinreactive T cells not only secrete IL-17 but also secrete IFN-γ and GM-CSF in contrast to T cells from healthy individuals 122 . These data suggest, as in the EAE animal model, that Th17 cells play a role in MS in human patients. These data also suggest that these Th17 cells are pathogenic due to their ability to cosecrete multiple cytokines. IL-17 levels have been reported to be increased in the CSF of MS patients during symptomatic relapse 123 , as well as in chronic lesions 116 . Interestingly, Th17 cells from patients with active symptoms of MS secrete less IL-10 compared to those who are clinically stable 124 . These data further suggest that Th17 cells from MS patients with stable disease are non-pathogenic with a regulatory property that might protect the host from aberrant cytotoxic responses against self.
Treg frequency and function have also been studied in MS. Although the frequency of Tregs is generally accepted as unaltered in MS patients 117, 125 , Tregs from MS patients show impaired ability to suppress proliferation and cytokine secretion of other CD4 + CD25 − T cells compared to healthy individuals 117 . Both the upregulation of IL-17 and down-regulation of Tregmediated immunity likely contribute to the pathogenesis of MS in humans.
Due to these Th17/Treg-related causes of MS, therapies that target these pathways are of great interest to the medical community. However, intriguingly, recent trials with IL-12/23 blockade (ustekinumab) did not show efficacy against the disease 126 . However, blockade of IL-17 with secukinumab showed some efficacy over placebo 127 . These preliminary findings will need to be evaluated more robustly in future trials. There is also growing interest in inducing suppressive Tregs in patients to reduce the severity of MS. For example, there is a new study led by Jewell at the Baltimore VA Medical Center that seeks to use nanotechnology to program myelin-specific Tregs in lymph nodes through exposure to myelin and toll-like receptor suppressive ligands, but data are not available from this investigation at this time (NIH Award 1I01BX003690-01) 128 . Perhaps targeting a combination of both Th17 and Treg pathways through IL-17 blockade and a boost of functional Tregs is necessary for disease control in patients with multiple sclerosis. Psoriasis MS is not the only disease where pathogenic Th17 cells have been shown to exacerbate autoimmune manifestations. Psoriasis is a chronic inflammatory skin disorder where the overproduction of IL-23 by keratinocytes supports pathogenic Th17 cells in the dermis 129 . Hallmark features of psoriasis include various factors: parakeratosis, elongation and bulbous widening of the rete ridges with thinning of suprapapillary plates, dilated blood vessels and rouleaux formation in the papillary dermis 118 . Patients with psoriasis have more IL-17 and IL-22-producing cells in their peripheral blood than healthy individuals 130 . Moreover, psoriatic lesions have been discovered to contain increased IL-17A, IL-17C, and IL-17F compared to non-lesioned skin biopsies [131] [132] [133] and are populated with more Th17 and Th1 cells 134 . T cell recruitment and proliferation are induced by CCL20 and IL-23 (secreted by APCs), while IFN-γ and various isoforms of IL-17 stimulate keratinocyte proliferation and APC activation in a cyclic manner [134] [135] [136] [137] . In addition to the strong link to Th17 hyperactivity, psoriasis has also been associated with altered Treg functionality. 140 . Therapies that may bolster or correct the faulty Treg function in these patients may also yield improved effects, but such therapies are not currently available. It is possible that modulation of low dose IL-2 or TGF-β could also bolster the generation of suppressive Treg cells in these patients while concomitantly suppressing Th1 or Th17 cells.
Other autoimmune diseases impacted by Th17/Treg axis: RA, IBD, SLE Similar to MS and psoriasis, it has become clear that the pathogenesis of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and systemic lupus erythematosus (SLE) are also influenced by an imbalance in Th17/Treg function. These autoimmune diseases are summarized in Table 1 . Clinical investigations are underway to understand how drugs that block the IL-17 and IL-23 pathway or potentiate Treg function impact RA, IBD, and SLE. More information on these findings is outlined in these references 119, [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] .
A pinch of salt to reduce autoimmunity? While an obvious way to treat autoimmunity in patients is by blunting the Th17 pathway via IL-17 or IL-23 blockade with FDAapproved drugs, holistic strategies involving simply changing the patient's diet or modulating the microbiota to dampen Th17-mediated diseases are becoming increasingly more appreciated. A high-salt diet has been shown to induce Th17 cells and exacerbate EAE 152 . This concept is supported by a recent report by Wilck and team, who found that a high-salt diet triggers an increased number of pathogenic Th17 cells in the peripheral blood of mice, correlating with destruction of the Lactobacillus species in the gut microbiome and hypertension 153, 154 . Repopulating the gut with Lactobacillus species was shown to mitigate the severity of EAE and hypertension 152, 153 . The high-salt diet similarly led to an increase in peripheral circulating Th17 cells in a healthy human cohort 153 . In a preclinical arthritis model, the gut microbe segmented filamentous bacterium (SFB) was also found to support Th17 cells and exacerbate autoimmunity 155 . While antibiotics have been shown to reduce SFB and lessen the pathogenesis of Th17 cells, thus reducing these autoimmune diseases, it is less clear how altering the salt intake or administering probiotics in human patients could impact disease outcome. Regardless, it is now clear that modulating the microbiome can also play a major role in shaping the biology of the Th17/Treg axis. As discussed below, we will review the important role of Th17 cells and Tregs in cancer progression as well as ways to manipulate these two subsets to augment cancer immunotherapy. cancer 156 . Today, it is widely accepted that chronic infection with bacteria, such as Helicobacter pylori 157 , or viruses, such as human papilloma virus 158 , can cause cancer. Although present day evidence for the role of Th17 cells in cancer is contradictory, excess inflammation from Th17 cells or too much immunosuppression induced by Treg cells may lead to carcinogenesis.
Th17 cells are found in human tumors 159, 160 . IL-17A promotes the proliferation of malignant cells and induces angiogenic constituents by stimulating fibroblasts to upregulate vascular endothelial growth factor (VEGF), resulting in tumor neovascularization 161, 162 . Whether Th17 cells promote or inhibit cancer development depends on the phenotype of the tumor. Protumorigenic neutrophils, recruited by IL-17, have been reported in breast cancers 163 . High IL-17A and RORγt expression correlated with reduced disease-free survival rates in patients with colorectal cancer 164 . In pancreatic cancer, increased IL-22 production by Th17 cells is associated with decreased survival rates in patients 165 . In non-small cell lung cancer, patients were found to have a greater ratio of Th17/Treg frequencies compared to healthy controls, which correlated with the levels of carcinoembryonic antigen (CEA) 166 . In breast cancer, though, IL-22 production correlates with decreased tumor formation and a positive prognosis 167 . In ovarian cancer, increased tumor-associated IL-17 predicted improved patient survival 160 . Treg cells, however, are often associated with tumor progression and reduced survival in cancer patients 168, 169 . GARP expression in tumors has been shown to enhance active TGF-β and support Treg induction in the cancer microenvironment, thus hindering immune responses 170 . Treg presence in the tumor microenvironment has been associated with more advanced stage of malignancy, presence of invasion, and worsened prognosis 168, 169 . Depletion of live Tregs in the murine tumor microenvironment prevented immunosuppression of tumorinfiltrating CD8 + T cells, allowing improved anti-tumor efficacy of endogenous effector T cells 171 . Apoptotic Tregs in the tumor, however, may also contribute to immune evasion. Recent work by the Zou lab revealed that oxidative stress in the tumor microenvironment induces Treg apoptosis, releasing large amounts of ATP, which is metabolized to immunosuppressive adenosine and signals through the A2a receptor (A2aR) 172 . This work suggests that selective depletion of Tregs in a patient's tumor with inhibition of the A2aR pathway could circumvent the immune-evasive tumor microenvironment and thus increase immunity to human malignancies 173 .
Immunotherapy: a shift in the paradigm? Despite the evidence suggesting a pro-tumorigenic role of Th17 cells and related cytokines, recent advances in the field of immunotherapy for treating cancer have suggested that Th17 cells may play a powerful role in antitumor immunity. In this case, tipping the Th17/Treg scale towards a dominant Th17 cell influence could be beneficial for patients with aggressive tumors. Herein, we will discuss preclinical and clinical findings that support further investigation of Th17 cells in therapeutically modulating tumor regression.
Adoptive cell transfer
Adoptive T cell transfer therapy (ACT) uses the patient's own T cells to target and kill tumor cells. In the clinic, T cells can be obtained and logarithmically expanded from the tumor (called tumor-infiltrating lymphocytes or TIL) or can be rendered antigenspecific via genetically engineering peripheral blood T cells using Chimeric Antigen Receptor (CAR) or T cell receptor (TCR) constructs 174 . Much of ACT has focused on using CD8 + T cells to treat cancer patients; however, CD8 + T cells tend to progressively lose antitumor function as they expand, showing reduced ability to persist and clear tumors in vivo 175 . Recent clinical trials have now shown that CD4
+ tumor-reactive T cells polarized to a Th1 subset are able to regress tumors in humans 176 , and in recently published work, human CD4 + T cells that express high levels of CD26 were found to cosecrete IL-17 and IFN-γ and be even more effective than CD8 + T cells when infused into mice bearing large human tumors 177 . However, based on preclinical work, efficacy may ultimately depend on the particular type of T helper subset infused into the cancer patient [178] [179] [180] [181] . Numerous laboratories have now discovered that Th17 cells can cause tumor regression to a greater extent than Th1 cells when transferred into mice 178, 179, 182, 183 . While the mechanism by which Th17 cells regress tumors is not fully understood, they may kill tumor cells through synergism with CD8 + T cells or by themselves via direct lysis 180, 181 . The enhanced ability of Th17 to ablate tumors has been attributed to a variety of characteristics. In culture, Th17 cell polarization is known to generate a more differentiated effector memory phenotype (CD62L lo , CCR7 lo ); However, paradoxically, after transfer, Th17 cells express high CCR7, Lef1, and Tcf7, indicating a durable stem memory phenotype 179 . In adoptive transfer therapy, it is interesting to note that the ability of Th17 cells to convert to a Th1-like phenotype and generate IFN-γ in vivo is critical for antitumor response 178, 179 . However, compared to their Th1 counterpart, Th17 cells persist far longer and at greater frequencies in the host 179 . Th17 cells are also resistant to apoptosis, which permits them to oppose activation-induced cell death (AICD) 184 . Finally, Bowers et al. recently reported that Th17 cells retain their antitumor efficacy and resist senescence compared to Th1 cells even after long term ex vivo expansion for nearly one month 185 . Given that a large number of T cells are needed to mediate curative responses in mice with large tumors, the fact that Th17 but not CD8 + T cells can expand to ample numbers without losing their therapeutic potency has significant implications for clinical translation.
Despite preclinical success with murine and human Th17 cells, this powerful lymphocyte population has not yet been transferred into patients. One current barrier to successful antitumor response in the clinic includes use of exhausted T cells that do not persist in the blood. Through use of Th17-polarizing conditions in vitro in the clinic, Muranski et al. 179 could generate a population that displays improved persistence and long-lived immunity. As many cytokines are needed to generate human Th17 cells, investigators seek to find other methods to effectively enrich and expand these cells without such cumbersome protocols. Most recently, it was demonstrated that CD26, a multifunctional ectoenzyme with costimulatory properties, was associated with enhanced Th17 cell function and activation 177 . In this work by Bailey and team, high levels of CD26 could be used to enrich human T cells with a type 17 phenotype 177, 186 . T cells with a high expression of CD26 are multifunctional, have enhanced migratory and stem-like properties, resist apoptosis, and have been shown to regress multiple tumors 177 . Conversely, T cells with low CD26 expression were regulatory T cells, as demonstrated by their high expression of classic hallmark molecules such as high CD25, low CD127 and high expression of Foxp3 and Helios 177 . While such characteristics of CD26 could be capitalized upon therapeutically by inducing CD26 high Th17 cells while concomitantly ablating CD26 low Tregs, the possibility of Th17-induced autoimmunity dictates caution for the safe translation of this putative exciting, and perhaps more effective therapy.
Checkpoint blockade
Monoclonal antibodies that inhibit suppressive regulatory receptors (checkpoints) on T cells regress various tumors in patients including melanoma, bladder, breast, renal cell, ovarian, lung, and colorectal cancers 187 . The role of Th17 cells or other IL-17-producing immune cells has not been fully described in the mechanism for checkpoint blockade therapy, yet immune-related adverse events (irAEs) are frequent toxicities reported with this therapy. Anti-PD-1 therapy has been associated with exacerbated degrees of colitis, pneumonitis, endocrinopathy, lichenoid reactions, eczema, vitiligo, psoriasis, and pemphigoid in patients [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] . Anti-CTLA-4 therapy with ipilumimab has been reported to induce even more toxic side effects than anti-PD-1 therapy, including colitis, arthritis, dermatitis, hepatitis, and endocrinopathies, with less frequent incidence of uveitis, myopathy, and nephritis [199] [200] [201] . Combination therapy with CTLA-4 and PD-1 blockade (ipilimumab and nivolumab, respectively) can result in tumor regression with concurrent autoimmune toxicities related to a secondary immune response and epitope spreading 202 . PD-1 blockade with nivolumab as a monotherapy in advanced melanoma has been shown to be nearly as effective as combination therapy with ipilumumab; both therapies show significantly increased overall survival compared to ipilumumab alone 203, 204 . Since the combination therapy induces a higher frequency of adverse events, treatment benefits should be weighed against risk of toxicity 205 . For many patients, these toxicities are not without benefit. Fortunately, irAEs are often self-limiting or can be managed with high dose corticosteroids or hormone replacement, and especially with ipilumimab, may correlate with antitumor response 200, 201 . Toxicities with ipilumimab have been associated with a greater likelihood of objective response in melanoma. Importantly, it should be noted that use of corticosteroids to treat irAEs has not significantly affected antitumor response [206] [207] [208] [209] [210] . Thus, it is important to understand the underlying reason why irAEs may be associated with better treatment outcome in cancer patients. These adverse events have prompted the search for immune system biomarkers predictive of therapy success. Interestingly, higher baseline IL-17 before treatment with ipilumimab has been associated with more advanced grade III irAEs 211 . Higher pretreatment serum levels of Th17 lineage related cytokines TGF-β and IL-6 have been associated with lack of melanoma progression and regression free survival with ipilumimab and interferon-α2b treatments, respectively 211, 212 . Thus, autoimmune toxicities have been correlated with IL-17 levels, while antitumor responses have been associated with autoimmune toxicity. Mounting evidence from these various findings warrants future investigations that precisely uncover the role of Th17 cells in modulating these toxic and antitumor events.
Two recent reports suggest that Th17 cells and IL-17 may play an important role in both the efficacy and toxicity of checkpoint blockade therapy in cancer patients. This concept was demonstrated in a 50-year-old male with a history of mild psoriasis and Crohn's disease who received PD-1 blockade (pembrolizumab) for metastatic colon cancer. The first two rounds of this therapy resulted in a remarkable 50% reduction in CEA 213 . Interestingly, after the third cycle of pembrolizumab, the patient displayed a severe psoriatic rash that covered 75% of his body along with increased abdominal pain and stool frequency. To resolve the skin manifestations, the patient was treated with secukinumab, an FDA-approved IL-17A blockade indicated for treatment of psoriasis. Although IL-17 blockade improved the symptoms of psoriasis and gastrointestinal pain, the anti-tumor activity was reduced as serum CEA returned to pretreatment levels 213 . Similarly, in a recent analysis of melanoma patients receiving PD-1 therapy, the frequency of IL-17-producing T helper cells was increased in responders to therapy versus non-responders, though monocytes were most predictive of response to therapy 214 . Given that several preclinical studies have suggested that Th17 cells and IL-17 may enhance or support tumor immunity, these clinical reports underscore the importance of studying the antitumor qualities of these effector Th17 cells in treating human patients.
The ultimate goal of the immunotherapy field is to uncouple toxicity from durable antitumor immunity. In the future, it is possible that the Th17/Treg axis could be effectively manipulated to augment tumor immunity while suppressing adverse immune side effects to healthy tissue. For example, it is possible that low dose IL-2 therapy following adoptive transfer of Th17 cells could mitigate prolonged autoimmunity once tumors have been cleared by elevating self-antigen-specific Tregs while still supporting antitumor Th17 and CD8 + T cells. Additionally, depletion of Tregs along with inhibition of the adenosine A2aR pathway could empower infiltrating effector immune cells to overcome the immunosuppressive tumor microenvironment. The potential in this field to treat and cure patients could be further enhanced through careful manipulation of both sides of this Th17/Treg balance.
CONCLUSIONS
The balance between Th17 and Treg T cells is critical for maintaining homeostasis. A Th17 dominance or dysfunctional Treg surveillance is associated with autoimmune disorders such as MS, psoriasis, RA, IBD, or SLE. Th17 cells and related cytokines can promote either tumorigenesis or tumor suppression, although this role is poorly understood. Future work in the field of immunotherapy in terms of adoptive transfer, vaccines and checkpoint blockade may provide new insights into the power of Th17 cells in regressing tumors, further enhancing our ability to harness the immune system against cancer. Future clinical trials may also use Tregs to quench immune responses to self-tissue without disturbing antitumor Th17 or CD8
+ T cell responses in order to maximize efficacy and minimize toxicity in caring for cancer patients. Indeed, these are exciting times in the field of cancer immunotherapy and mounting evidence is converging on the potential to exploit the Th17/Treg axis to profoundly impact the life of patients with cancer and autoimmunity.
